Sangamo Therapeutics, Inc. (SGMO) News
Filter SGMO News Items
SGMO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SGMO News Highlights
- For SGMO, its 30 day story count is now at 7.
- Over the past 28 days, the trend for SGMO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about SGMO are GENE, AG and CELL.
Latest SGMO News From Around the Web
Below are the latest news stories about SANGAMO THERAPEUTICS INC that investors may wish to consider to help them evaluate SGMO as an investment opportunity.
The Petri Dish: Takeda scores win from Nimbus licensing deal; Biogen exits partnershipTakeda paid Nimbus Therapeutics $4 billion for a psoriasis drug in December. It just met its primary goal in a midstage trial. |
Sangamo (SGMO) Loses -37.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerThe heavy selling pressure might have exhausted for Sangamo (SGMO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
Two Big Pharma Companies Bow Out Of Neurology Drug Partnerships With SangamoTwo big-name partners have walked away from partnerships with Sangamo Therapeutics Inc (NASDAQ: SGMO) over a few days. On Friday, the company filed an SEC document, Novartis AG (NYSE: NVS) terminated the Collaboration and License Agreement dated July 27, 2020, effective June 11, 2023. The Novartis and Sangamo were engaged in programs to research gene regulation therapies to treat three neurodevelopment disorders. Novartis has indicated to Sangamo that the termination relates to a recent strategi |
10 Companies That Had Tons of Money in SVB When It CollapsedSilicon Valley Bank is gone but its clients are still here. |
Sangamo (SGMO) Loses -24.09% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerSangamo (SGMO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
In the wake of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) latest US$56m market cap drop, institutional owners may be forced to take severe actionsKey Insights Institutions' substantial holdings in Sangamo Therapeutics implies that they have significant influence... |
Sickle-cell gene therapy developer stops program, cuts half of staffGene therapy offered hope for thousands of sickle cell disease patients. Now many are ending their programs. |
Sangamo Therapeutics Shares Updated Data From Fabry Gene Therapy Study, Says It Shows Evidence Of Clinical BenefitSangamo Therapeutics Inc (NASDAQ: SGMO) announced updated preliminary data as of October 20, 2022, the cutoff date from the Phase 1/2 STAAR study of isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for Fabry disease. As of the November 15, 2022, supplemental cutoff date, 13 patients exhibited supraphysiological levels of α-Gal A activity, sustained for over two years for the patient with the longest follow-up. All five patients who began the dose escalation pha |
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Tops Revenue EstimatesSangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial ResultsBRISBANE, Calif., February 22, 2023--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS |